S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Bangladesh seeks China help to repatriate Rohingya refugees
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Bangladesh seeks China help to repatriate Rohingya refugees
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Bangladesh seeks China help to repatriate Rohingya refugees
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Bangladesh seeks China help to repatriate Rohingya refugees
NASDAQ:PRLD

Prelude Therapeutics - PRLD Stock Forecast, Price & News

$6.17
+0.44 (+7.68%)
(As of 08/5/2022 08:49 PM ET)
Add
Compare
Today's Range
$5.55
$6.21
50-Day Range
$4.20
$6.17
52-Week Range
$3.87
$43.55
Volume
89,300 shs
Average Volume
241,734 shs
Market Capitalization
$294.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.20

Prelude Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
113.9% Upside
$13.20 Price Target
Short Interest
Bearish
8.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$42,300 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.49) to ($2.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

604th out of 1,283 stocks

Pharmaceutical Preparations Industry

286th out of 615 stocks

PRLD stock logo

About Prelude Therapeutics (NASDAQ:PRLD) Stock

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Prelude Therapeutics Stock Performance

PRLD Stock opened at $6.17 on Monday. The company has a market capitalization of $294.28 million, a P/E ratio of -2.39 and a beta of 0.75. Prelude Therapeutics has a 52-week low of $3.87 and a 52-week high of $43.55. The business has a 50-day simple moving average of $5.16 and a two-hundred day simple moving average of $6.56.

Prelude Therapeutics (NASDAQ:PRLD - Get Rating) last announced its earnings results on Tuesday, May 10th. The company reported ($0.63) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.05. As a group, sell-side analysts forecast that Prelude Therapeutics will post -2.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on PRLD shares. HC Wainwright reduced their target price on Prelude Therapeutics from $62.00 to $16.00 and set a "buy" rating for the company in a research note on Thursday, May 12th. Jefferies Financial Group started coverage on Prelude Therapeutics in a research note on Friday, July 29th. They issued a "buy" rating and a $9.00 target price for the company. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Prelude Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $13.20.

Insider Transactions at Prelude Therapeutics

In other Prelude Therapeutics news, CFO Laurent Chardonnet bought 10,000 shares of the business's stock in a transaction dated Wednesday, June 1st. The shares were purchased at an average price of $4.23 per share, for a total transaction of $42,300.00. Following the purchase, the chief financial officer now directly owns 24,500 shares of the company's stock, valued at $103,635. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 77.38% of the company's stock.

Receive PRLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRLD Stock News Headlines

Expert Ratings for Prelude Therapeutics
Prelude Therapeutics Incorporated (PRLD)
See More Headlines
Receive PRLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRLD Company Calendar

Last Earnings
5/10/2022
Today
8/08/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRLD
Fax
N/A
Employees
116
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.20
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+113.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-111,690,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.06 per share

Miscellaneous

Free Float
11,223,000
Market Cap
$294.28 million
Optionable
Not Optionable
Beta
0.75

Key Executives

  • Dr. Krishna Vaddi D.V.M. (Age 56)
    Ph.D., Founder, CEO & Director
    Comp: $809.88k
  • Dr. Peggy A. Scherle Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $564.27k
  • Dr. Andrew P. Combs Ph.D. (Age 56)
    Exec. VP & Head of Chemistry
    Comp: $562.46k
  • Dr. Edna Huang M.D. (Age 49)
    Pres & Chief Medical Officer
  • Mr. Laurent Chardonnet (Age 57)
    Chief Financial Officer
  • Ms. Aimee Crombie Ph.D.
    Sr. VP and Head of Strategic Planning & Operations
  • Dr. Madhu Pudipeddi Ph.D.
    Sr. VP of Technical Operations
  • Ms. Michele Porreca M.B.A.
    Chief People Officer
  • Mr. Naveen Babbar Ph.D.
    Sr. VP of Translation Medicine













PRLD Stock - Frequently Asked Questions

Should I buy or sell Prelude Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prelude Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Prelude Therapeutics stock.
View analyst ratings for Prelude Therapeutics
or view top-rated stocks.

What is Prelude Therapeutics' stock price forecast for 2022?

5 analysts have issued 12 month target prices for Prelude Therapeutics' shares. Their PRLD stock forecasts range from $9.00 to $19.00. On average, they predict Prelude Therapeutics' stock price to reach $13.20 in the next year. This suggests a possible upside of 113.9% from the stock's current price.
View analysts' price targets for Prelude Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Prelude Therapeutics' stock price performed in 2022?

Prelude Therapeutics' stock was trading at $12.45 at the start of the year. Since then, PRLD shares have decreased by 50.4% and is now trading at $6.17.
View the best growth stocks for 2022 here
.

When is Prelude Therapeutics' next earnings date?

Prelude Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Prelude Therapeutics
.

How were Prelude Therapeutics' earnings last quarter?

Prelude Therapeutics Incorporated (NASDAQ:PRLD) issued its earnings results on Tuesday, May, 10th. The company reported ($0.63) EPS for the quarter, topping analysts' consensus estimates of ($0.68) by $0.05.

When did Prelude Therapeutics IPO?

(PRLD) raised $149 million in an IPO on Friday, September 25th 2020. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities acted as the underwriters for the IPO.

What is Prelude Therapeutics' stock symbol?

Prelude Therapeutics trades on the NASDAQ under the ticker symbol "PRLD."

Who are Prelude Therapeutics' major shareholders?

Prelude Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Commonwealth Equity Services LLC (0.03%). Company insiders that own Prelude Therapeutics stock include Andrew Combs, Brian Piper, Christopher Pierce, David J Mauro, David J Mauro, Deborah Morosini, Laurent Chardonnet and Peggy Scherle.
View institutional ownership trends for Prelude Therapeutics
.

How do I buy shares of Prelude Therapeutics?

Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prelude Therapeutics' stock price today?

One share of PRLD stock can currently be purchased for approximately $6.17.

How much money does Prelude Therapeutics make?

Prelude Therapeutics (NASDAQ:PRLD) has a market capitalization of $294.31 million. The company earns $-111,690,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis.

How many employees does Prelude Therapeutics have?

Prelude Therapeutics employs 116 workers across the globe.

How can I contact Prelude Therapeutics?

The official website for Prelude Therapeutics is www.preludetx.com. The company can be reached via phone at 302-467-1280 or via email at prelude@argotpartners.com.

This page (NASDAQ:PRLD) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.